Skip to content

Dyne Therapeutics, Inc.

DYN

CIK 0001818794 · Pharmaceutical Preparations · Nasdaq

← back to feed
Revenue (TTM)
—
Q1 Mar 2026
Net Income (TTM)
−$455.11M
−40.6% YoY Q1 Mar 2026
EPS Diluted (TTM)
−$3.51
−3.0% YoY Q1 Mar 2026
Gross Margin
—
Q1 Mar 2026
Operating Margin
—
Q1 Mar 2026
Net Margin
—
Q1 Mar 2026
Free Cash Flow (TTM)
−$377.88M
Q1 Mar 2026
Cash
$753.1M
Q1 Mar 2026
Total Debt
$9.94M
Q1 Mar 2026
Shares Outstanding
142.82M sh
Q1 Mar 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings